Effect Of Azithromycin in Women at Risk of Preterm Labour

Last updated: July 25, 2023
Sponsor: Beni-Suef University
Overall Status: Active - Not Recruiting

Phase

2/3

Condition

Pregnancy

Miscarriage

Pregnancy Complications

Treatment

azithromycin

Clinical Study ID

NCT05971654
Azithromycin preterm
  • Ages 20-40
  • Female

Study Summary

The aim of this study is to evaluate the benefit of the addition of azithromycin to standard treatments to prolong pregnancy in women having intact membranes and is at risk of or in preterm labour.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • 24 < Pregnancy <37 weeks of gestation.
  • Threat or history of preterm labour.
  • Preterm labour itself (Non established)

Exclusion

Exclusion Criteria:

  • antibiotics use within 14 days (except for pericerclage prophylaxis, or streptococcusB prophylaxis);
  • PPROM; and fetal extraction required <37 weeks.
  • Current or past history of medical diseases (Diabetes Milletus, Hypertension, SystemicLupus Erythematosus, Cardiac diseases, etc ).
  • Adverse perinatal outcome due to abdominal trauma.
  • Structural fetal anomalies detected during anomaly scan.
  • Allergy to Azithromycin.

Study Design

Total Participants: 200
Treatment Group(s): 1
Primary Treatment: azithromycin
Phase: 2/3
Study Start date:
July 30, 2023
Estimated Completion Date:
May 30, 2024

Study Description

Study Design:

Comparative controlled study.

Study site :

The study will be conducted at the department of Obstetrics and Gynecology at Beni-Suef University Hospital.

Study period:

The study will be conducted from 15th September 2022 till reaching the target number.

Study Population The control group will include pregnant women, having intact membranes and are at risk of or in preterm labour, administrating the standard treatments for prolongation of pregnancy.

The test group will involve pregnant women, having intact membranes and are at risk of or in preterm labour, administrating the standard treatments for prolongation of pregnancy plus prophylactic azithromycin.:500 mg PO once for 5 days every month.

Sample size:

The sample size was determined using G*Power Version 3.1.9.2 [computer software] (Franz Faul, Kiel, Germany),Power analysis for a chi-square test was conducted in G-POWER to determine a sufficient sample size using an alpha error of probability of 0.05, power of 0.95, a medium effect size (w = 0.3) and 1 degree of freedom. Based on the aforementioned assumptions, the desired sample size is 145. By calculating 25% drop out, so the least total sample size in both groups will be 200 patients (95 patients in each group).

Each patient will be subjected to:

Thorough history taking and examination. Investigations: Complete blood picture (CBC), bleeding profile , kidney function tests and liver function tests will be done.

Ultrasound: 2D Ultrasound assessing :

It will be carried out in Gynecology and Obstetrics department in Beni-Suef University Hospital, ultrasonography criteria: Ultrasound biometry of the fetus is now the gold standard for assessing fetal growth. The measurements most commonly used are the biparietal diameter, head circumference, abdominal circumference and femur length

Connect with a study center

  • Beni-suef university Hospital

    Banī Suwayf, Beni Suef 62521
    Egypt

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.